A case of aquagenic urticaria successfully treated with omalizumab

Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence

“…Only one case of omalizumab treatment in a patient with aquagenic urticaria was identified. 76 A patient with a 2-year history of aquagenic urticaria whose condition was uncontrolled by previous medications, including montelukast, cetirizine, loratadine, ranitidine, diphenhydramine, and hydroxyzine, was started on 300 mg of omalizumab per month. Symptoms completely resolved after 2 omalizumab doses, and the patients was able to go swimming for the first time in many years and discontinued other medications without symptom recurrence.…”

Management of chronic inducible urticaria according to the guidelines: A prospective controlled study

“…In 2014, omalizumab was approved by the FDA for AH-refractory CSU patients [39,40] and it was recommended by JTFPP, EAACI/GA 2 LEN/EDF/WAO and BSACI guidelines due to its efficacy and safety [5,8,9]. Efficacy of omalizumab for CSU has been shown by placebo controlled clinical trials [39,[40][41][42][43][44][45], while there are just case reports and case series in the literature for CIndU [11,17,[46][47][48][49][50]. There are on-going trials evaluating the efficacy of omalizumab in different types of CIndU which have not been published yet [CUTEX (NCT01580592), UFO (NCT02169115), XOLUS (NCT02262130), CUN-OMAL-UCOL (NCT02012387)].…”

Evidence for histamine release in chronic inducible urticaria – A systematic review

“…Also, an in vitro study of basophils from patients with AquaU, showed histamine release in response to challenge with all of 4 dilutions of human callus extract ( 90 ). FgAH 1 and sgAH 1 lead to benefit in most patients ( 91 – 93 ), and up-dosing can improve the response ( 94 , 95 ).…”